The entire team — including the stoma therapist, dietitian, psychologist, sexologist, and surgeon — had the opportunity to attend the 44th Enterostomal Therapy Nurses Conference. They shared their experience and insights on the digestive surgery care pathway at the Tivoli-Ducos Clinic and the Bordeaux Colorectal Institute (BCI).
BCI is pleased to take part in the continuing education day organized by our colleagues in gastroenterology, and to contribute as a speaker on the topic: Localized rectal cancer – Who should not undergo surgery in 2025?
We are delighted to officially welcome Dr. Barbara NOIRET — a skilled and compassionate surgeon — who has decided to continue the journey with us and expand the BCI team.
Three clinical trials were highlighted by Prof. DENOST and Dr. NOIRET during the "Best Oral Presentations" session, including a clinical case and a video communication, on the following topics:
It is an honor to have been appointed President of the Program Committee of the ESCP Congress of the Future for the next 3 years and thus to participate in writing the program of the next congress which will take place in Paris from September 10 to 12, 2025.
Invited as a speaker at the 3rd Colorectal Congress organized in Milan to discuss the advantages and disadvantages of mechanical anastomoses performed transanal approach (TTSS technique) during rectal surgery performed by laparoscopy approach in men and women with rectal cancer.
We are very pleased to announce the election of Professor Quentin DENOST as President of the GRECCAR Group (Rectal Cancer Research Group) for the next 4 years.
We are pleased to have been accepted the abstract "Organ preservation in rectal cancer management : A prospective GRECCAR SNAPSHOT" for presentation at the 2025 ASCRS Annual Scientific Meeting.
The results of the GRECCAR 4 and PRODIGE 23 randomized trials on the total neaoadjuvant of adjuvant chemotherapy after rectal cancer and the results of the GRECCAR 12 randomized trial on the rôle of neoadjuvant chemotherapy in organ preservation were also selected for presentation at the meeting.
The BCI will attend the JFHOD to present "The Oncological Impact of Adjuvant Chemotherapy After Rectal Resection for Cancer in the TNT Era: Results of Two Randomized Controlled Trials: GRECCAR 4 and PRODIGE 23."
The results presented in this trial are from two randomized controlled trials, GRECCAR 4 and PRODIGE 23, in which the BCI participated.
This congress will discuss the placement or not of a stoma depending on the patients' risk factors (GRECCAR 17 trial) but also the organ preservation strategy and the management of patients with rectal cancer with a near-complete response (GRECCAR 20 trial).
220 rue Mandron
33000 Bordeaux
+33 (0)5 47 50 15 75
